Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial.

Saved in:
Bibliographic Details
Title: Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial.
Authors: Jairath V; Division of Gastroenterology, Department of Medicine, Western University, London, ON, Canada; Department of Epidemiology and Biostatistics, Western University, London, ON, Canada. Electronic address: vjairath@uwo.ca., Danese S; Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy., D'Haens GR; Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre, Academic Medical Centre, Amsterdam, Netherlands., Feagan BG; Division of Gastroenterology, Department of Medicine, Western University, London, ON, Canada; Department of Epidemiology and Biostatistics, Western University, London, ON, Canada., Peyrin-Biroulet L; Department of Gastroenterology, CHRU Nancy, INSERM NGERE, Université de Lorraine, Vandœuvre-lès-Nancy, France; Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Quebec, Canada., Sands BE; The Dr Henry D Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Gaemers I; Tytgat Institute for Liver and Intestinal Research, Amsterdam UMC, Amsterdam, Netherlands., Westfall M; Inotiv, Nashville, TN, USA., Terry AQ; Sorriso Pharmaceuticals, Sandy, UT, USA; Magnify at CNSI, UCLA, Los Angeles, CA, USA., Roberts KJ; Sorriso Pharmaceuticals, Sandy, UT, USA; Magnify at CNSI, UCLA, Los Angeles, CA, USA., Barbat S; Sorriso Pharmaceuticals, Sandy, UT, USA., Wedel P; Sorriso Pharmaceuticals, Sandy, UT, USA., Benson JM; Sorriso Pharmaceuticals, Sandy, UT, USA., Sattler C; Sorriso Pharmaceuticals, Sandy, UT, USA.
Source: The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2026 Jan; Vol. 11 (1), pp. 34-45. Date of Electronic Publication: 2025 Nov 13.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Multicenter Study
Journal Info: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101690683 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2468-1253 (Electronic) NLM ISO Abbreviation: Lancet Gastroenterol Hepatol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2468-1253
DOI:10.1016/S2468-1253(25)00296-1